Table slides from real investment banking decks

Browse 3,164 presentations with a table slide. Search and filter the decks below.

I'm feeling lucky

145–192 of 3,164 presentationsPage 4 of 66

Table slide 5 from Aeglea Biotherapeutics — Redefining the Possible. Human Enzyme Therapies for People with Rare Diseases

Aeglea Biotherapeutics — Redefining the Possible. Human Enzyme Therapies for People with Rare Diseases · Slide 5

2023

Table slide 7 from Aeglea Biotherapeutics — Reimagining The Potential Of Human Enzyme Therapeutics

Aeglea Biotherapeutics — Reimagining The Potential Of Human Enzyme Therapeutics · Slide 7

2020

Table slide 7 from Aeglea Biotherapeutics — Reimagining The Potential Of Human Enzyme Therapeutics

Aeglea Biotherapeutics — Reimagining The Potential Of Human Enzyme Therapeutics · Slide 7

2021

Table slide 7 from Aeglea Biotherapeutics — Reimagining The Potential Of Human Enzyme Therapeutics

Aeglea Biotherapeutics — Reimagining The Potential Of Human Enzyme Therapeutics · Slide 7

2020

Table slide 5 from Aeglea Biotherapeutics — Transaction & Overview

Aeglea Biotherapeutics — Transaction & Overview · Slide 5

2023

Table slide 34 from Aerofarms

Aerofarms · Slide 34

2021

Table slide 45 from Aerofarms

Aerofarms · Slide 45

2021

Table slide 24 from Affirm — Affirm Financial Model Information Session

Affirm — Affirm Financial Model Information Session · Slide 24

2023

Table slide 87 from Affirm — Affirm Investor Forum

Affirm — Affirm Investor Forum · Slide 87

2023

Table slide 19 from Affirm — FY Q1 2022 Earnings Supplement

Affirm — FY Q1 2022 Earnings Supplement · Slide 19

2022

Table slide 25 from Affirm — FY Q1 2023 Earnings Supplement

Affirm — FY Q1 2023 Earnings Supplement · Slide 25

2022

Table slide 26 from Affirm — FY Q1 2024 Earnings Supplement

Affirm — FY Q1 2024 Earnings Supplement · Slide 26

2023

Table slide 22 from Affirm — FY Q2 2022 Earnings Supplement

Affirm — FY Q2 2022 Earnings Supplement · Slide 22

2022

Table slide 25 from Affirm — FY Q2 2023 Earnings Supplement

Affirm — FY Q2 2023 Earnings Supplement · Slide 25

2023

Table slide 26 from Affirm — FY Q2 2024 Earnings Supplement

Affirm — FY Q2 2024 Earnings Supplement · Slide 26

2024

Table slide 27 from Affirm — FY Q2 2025 Earnings Supplement

Affirm — FY Q2 2025 Earnings Supplement · Slide 27

2025

Table slide 21 from Affirm — FY Q3 2021 Earnings Supplement

Affirm — FY Q3 2021 Earnings Supplement · Slide 21

2021

Table slide 22 from Affirm — FY Q3 2022 Earnings Supplement

Affirm — FY Q3 2022 Earnings Supplement · Slide 22

2022

Table slide 25 from Affirm — FY Q3 2023 Earnings Supplement

Affirm — FY Q3 2023 Earnings Supplement · Slide 25

2023

Table slide 24 from Affirm — FY Q4 2021 Earnings Supplement

Affirm — FY Q4 2021 Earnings Supplement · Slide 24

2021

Table slide 24 from Affirm — FY Q4 2022 Earnings Supplement

Affirm — FY Q4 2022 Earnings Supplement · Slide 24

2022

Table slide 26 from Affirm — FY Q4 2023 Earnings Supplement

Affirm — FY Q4 2023 Earnings Supplement · Slide 26

2023

Table slide 27 from Affirm — FY Q4 2024 Earnings Supplement

Affirm — FY Q4 2024 Earnings Supplement · Slide 27

2024

Table slide 20 from Affirm — Investor Presentation

Affirm — Investor Presentation · Slide 20

2023

Table slide 20 from Affirm — Investor Presentation

Affirm — Investor Presentation · Slide 20

2022

Table slide 21 from Affirm — Investor Presentation

Affirm — Investor Presentation · Slide 21

2022

Table slide 30 from Affirm — Welcome to the Affirm Investor Forum

Affirm — Welcome to the Affirm Investor Forum · Slide 30

2021

Table slide 4 from Agrofresh — AgroFresh Solutions, Inc.

Agrofresh — AgroFresh Solutions, Inc. · Slide 4

2021

Table slide 5 from Agrofresh — AgroFresh Solutions, Inc.

Agrofresh — AgroFresh Solutions, Inc. · Slide 5

2021

Table slide 5 from Agrofresh — AgroFresh Solutions, Inc. Fourth Quarter 2021 Supplemental Earnings Presentation

Agrofresh — AgroFresh Solutions, Inc. Fourth Quarter 2021 Supplemental Earnings Presentation · Slide 5

Table slide 13 from Agrofresh — AgroFresh Solutions, Inc. Investor Presentation

Agrofresh — AgroFresh Solutions, Inc. Investor Presentation · Slide 13

2022

Table slide 13 from Agrofresh — AgroFresh Solutions, Inc. Investor Presentation

Agrofresh — AgroFresh Solutions, Inc. Investor Presentation · Slide 13

2022

Table slide 13 from Agrofresh — AgroFresh Solutions, Inc. Investor Presentation

Agrofresh — AgroFresh Solutions, Inc. Investor Presentation · Slide 13

2022

Table slide 13 from Agrofresh — AgroFresh Solutions, Inc. Investor Presentation

Agrofresh — AgroFresh Solutions, Inc. Investor Presentation · Slide 13

2022

Table slide 13 from Agrofresh — AgroFresh Solutions, Inc. Investor Presentation

Agrofresh — AgroFresh Solutions, Inc. Investor Presentation · Slide 13

2022

Table slide 13 from Agrofresh — AgroFresh Solutions, Inc. Investor Presentation

Agrofresh — AgroFresh Solutions, Inc. Investor Presentation · Slide 13

2022

Table slide 5 from Agrofresh — AgroFresh Solutions, Inc. Third Quarter 2021 Supplemental Earnings Presentation

Agrofresh — AgroFresh Solutions, Inc. Third Quarter 2021 Supplemental Earnings Presentation · Slide 5

Table slide 6 from Agrofresh — First Quarter 2022

Agrofresh — First Quarter 2022 · Slide 6

Table slide 7 from Agrofresh — Second Quarter & First Half 2022

Agrofresh — Second Quarter & First Half 2022 · Slide 7

2022

Table slide 6 from Agrofresh — Third Quarter 2022

Agrofresh — Third Quarter 2022 · Slide 6

2022

Table slide 42 from Airtel Africa — Airtel Africa plc

Airtel Africa — Airtel Africa plc · Slide 42

2022

Table slide 33 from Airtel Africa — Airtel Africa plc

Airtel Africa — Airtel Africa plc · Slide 33

2020

Table slide 44 from Airtel Africa — Airtel Africa plc

Airtel Africa — Airtel Africa plc · Slide 44

2021

Table slide 3 from Akouos — Title Slide

Akouos — Title Slide · Slide 3

2020

Table slide 8 from Albireo Pharma — ASSERT Topline Data Results

Albireo Pharma — ASSERT Topline Data Results · Slide 8

2022

Table slide 9 from Aldeyra Therapeutics — Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy

Aldeyra Therapeutics — Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy · Slide 9

2022

Table slide 9 from Alkermes — A Clear Investment Thesis

Alkermes — A Clear Investment Thesis · Slide 9

2023

Table slide 9 from Alkermes — Alkermes: A Clear Investment Thesis

Alkermes — Alkermes: A Clear Investment Thesis · Slide 9

2023